Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX AMZN BIIB IBB TSLA WYNN ALXN GMCR AMGN COST TRIP WDC VRTX BEAV QCOR AAPL SNDK GILD
Nyse: PXD V ACT IVV IBM GS SPG AGN LMT LNKD PRGO FDX TWC XEC MMM CVX BA NOC TMO
New Highs: SHW IVV SPG XEC PII HUM NOC BXP WLP CAT NSC SBAC APA SIAL UNP HON CI MJN AMT MCO

The Hot Industries

Health Care Plans 3
Railroads 2
Independent Oil & Gas 2

The Hot Sectors

Services 4
Industrial Goods 3
Healthcare 3

CELG Stock Chart


CELG
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

5,100
Monthly

Website:

http://www.celgene.com

CELG Celgene Corporation

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company’s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company’s pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

favicon

Celgene (CELG) Set to Beat Earnings Estimates on Strong Revs - Analyst Blog

22 Jul 2014, 3:56 pmCelgene Corporation ( CELG ) is set to report second quarter 2014 results on Jul 24 before market opens. Last quarter, the company had delivered an earnings surprise of 2.82%. Let's see how things are shaping up for this
favicon

Stock Market News for July 21, 2014 - Market News

21 Jul 2014, 9:53 amStock Market News for July 21, 2014 - Market News
favicon

Stock Market News for July 21, 2014

21 Jul 2014, 7:41 amUpbeat earnings results coupled with gains in bio-tech and Internet stocks helped benchmarks rebound to the green on Friday
favicon

The Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene

17 Jul 2014, 6:12 amThe Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene
favicon

Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog

16 Jul 2014, 8:47 amBiotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
favicon

Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM

10 Jul 2014, 4:17 amSearch Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Tuesday's Mad Money on CNBC: WMB data by YCharts Williams Companies : Investors looking for a bargain should look no further than this top performer from last quarter, Cramer told viewers. AA data by YCharts ...
favicon

Celgene's Otezla fails trial

9 Jul 2014, 4:45 pmBig-cap biotech Celgene (CELG) said that its new drug failed a trial for an inflammatory spinal disease, but the stock rebounded from a big drop early Wed. as analysts said the news wasn't a surprise. ...
favicon

Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback

9 Jul 2014, 10:37 amShares of Celgene (NASDAQ: CELG ) have been volatile since the company announced  weak Phase III trial results  for OTEZLA Wednesday morning. The stock was trading in the red during the pre-market session, ...
favicon

Jim Cramer's Top Stock Picks: CELG GSAT FCX SBUX

2 Jul 2014, 4:18 amSearch Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Tuesday's Mad Money on CNBC: CELG data by YCharts Celgene : Cramer said biotech is back, and his perennial fave Celgene remains at the top of his list of winners. GSAT data by YCharts Globalstar : Cramer said ...
favicon

Celgene Stockholders Approve Two-for-One Stock Split

24 Jun 2014, 1:04 amSUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that its stockholders approved a two-for-one stock split and an increase from 575 million to 1,150 million in the number of authorized shares of the Company's common stock at the Company’s Annual Meeting of Stockholders on June 18, 2014. Based on the total number of shares of common stock outstanding as of June 17 ...